Schlenker MB, Thiruchelvam D, Redelmeier DA.
University of Toronto, Toronto, ON, Canada.
Am J Ophthalmol 2015;160:569–80.
Shahram Kashani’s review: The aim of this study was to evaluate the risk of thromboembolic disease following intravitreal injection of bevacizumab or ranibizumab for the management of wet age-related macular degeneration or macular edema. This was a population-based cross-over analysis with self-matched historical control data (i.e. each patient was their own control). A total of 57919 patients were included in the study and all were >65years of age.
Thromboembolic events that had occurred 1–4years before treatment were compared with events occurring ≤1year after initiation of treatment. The authors also examined falls, depression, hip fractures, cardiac failure, angina, and total emergencies. The data were collected in Ontario, Canada, where those aged >65years of age have access to universal healthcare insurance. The database used allowed the authors to gather all the information required for analysis. However, it has some limitations, with no information available on visual acuity, presence of disease in the fellow eye, reason for anti-vascular endothelial growth factor (VEGF) treatment, or blood pressure measurements.